Home Cart Sign in  
Chemical Structure| 364622-82-2 Chemical Structure| 364622-82-2

Structure of Doripenem Monohydrate
CAS No.: 364622-82-2

Chemical Structure| 364622-82-2

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Doripenem Hydrate is an ultra-broad spectrum carbapenem derivative antibacterial agent used to treat complicated urinary infection including Pyelonephritis caused by E.coli.

Synonyms: Doripenem hydrate; S 4661 monohydrate; S-4661

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Doripenem Monohydrate

CAS No. :364622-82-2
Formula : C15H26N4O7S2
M.W : 438.52
SMILES Code : O=C(C(N12)=C(S[C@@H]3CN[C@H](CNS(=O)(N)=O)C3)[C@H](C)[C@]2([H])[C@@H]([C@H](O)C)C1=O)O.O
Synonyms :
Doripenem hydrate; S 4661 monohydrate; S-4661
MDL No. :MFCD09749887
InChI Key :NTUBEBXBDGKBTJ-WGLOMNHJSA-N
Pubchem ID :636377

Safety of Doripenem Monohydrate

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302
Precautionary Statements:P280-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
Caco-2 cells 50 mM 24 h To investigate the effect of Doripenem on gut microbiota composition, results showed Doripenem had similar effects on microbiota as meropenem trihydrate but differed from tobramycin. Arch Toxicol. 2022 Dec;96(12):3291-3303.
mutM mutant 8 mg/L 48 h Evaluate the bactericidal activity of polymyxin B alone, showing initial rapid killing followed by regrowth Antimicrob Agents Chemother. 2016 Apr 22;60(5):2870-80.
mutS mutant 8 mg/L 48 h Evaluate the bactericidal activity of polymyxin B alone, showing initial rapid killing followed by regrowth Antimicrob Agents Chemother. 2016 Apr 22;60(5):2870-80.
wild-type PAO1 8 mg/L 48 h Evaluate the bactericidal activity of polymyxin B alone, showing initial rapid killing followed by regrowth Antimicrob Agents Chemother. 2016 Apr 22;60(5):2870-80.
Escherichia coli 0.375 µg/ml-8 µg/ml 24 h To evaluate the bactericidal activity of doripenem, polymyxin B, and rifampin in combination. Results showed that the triple combination was bactericidal against 5/5 E. coli isolates. Antimicrob Agents Chemother. 2010 Jun;54(6):2732-4.
Pseudomonas aeruginosa 0.375 µg/ml-8 µg/ml 24 h To evaluate the bactericidal activity of doripenem, polymyxin B, and rifampin in combination. Results showed that the triple combination was bactericidal against 5/5 P. aeruginosa isolates. Antimicrob Agents Chemother. 2010 Jun;54(6):2732-4.
Acinetobacter baumannii 0.375 µg/ml-8 µg/ml 24 h To evaluate the bactericidal activity of doripenem, polymyxin B, and rifampin in combination. Results showed that the triple combination was bactericidal against 3/5 A. baumannii isolates. Antimicrob Agents Chemother. 2010 Jun;54(6):2732-4.
Klebsiella pneumoniae 0.375 µg/ml-8 µg/ml 24 h To evaluate the bactericidal activity of doripenem, polymyxin B, and rifampin in combination. Results showed that the triple combination was bactericidal against 4/5 K. pneumoniae isolates. Antimicrob Agents Chemother. 2010 Jun;54(6):2732-4.
Streptococcus pneumoniae IU1945 0.0042±0.0001 μg/ml 30 min Evaluate the inhibitory effect of Doripenem on PBP3, IC50 was 0.0042 μg/ml. Antimicrob Agents Chemother. 2015;59(6):3548-55.
Streptococcus pneumoniae IU1945 0.0082±0.0009 μg/ml 30 min Evaluate the inhibitory effect of Doripenem on PBP2x, IC50 was 0.0082 μg/ml. Antimicrob Agents Chemother. 2015;59(6):3548-55.
Streptococcus pneumoniae IU1945 0.0085 ± 0.0013 μg/ml 30 min Evaluate the inhibitory effect of Doripenem on PBP1a, IC50 was 0.0085 μg/ml. Antimicrob Agents Chemother. 2015;59(6):3548-55.
Multidrug-resistant A. baumannii (MDR A. baumannii) 8 µg/mL 24 h Evaluate the synergistic effect and bactericidal activity of Doripenem in combination with Colistin or Tigecycline. Results showed a high synergy rate (53.6%) with Colistin-Doripenem combination, while a lower synergy rate (14.3%) was observed with Doripenem-Tigecycline combination. Ann Lab Med. 2016 Mar;36(2):124-30.
Extensively drug-resistant A. baumannii (XDR A. baumannii) 8 µg/mL 24 h Evaluate the synergistic effect and bactericidal activity of Doripenem in combination with Colistin or Tigecycline. Results showed the highest synergy rate (53.6%) and bactericidal activity (75.4%) with Colistin-Doripenem combination, while the lowest synergy rate (14.5%) was observed with Doripenem-Tigecycline combination. Ann Lab Med. 2016 Mar;36(2):124-30.
Pseudomonas aeruginosa FADDI PA070 2.0 mg/L 240 h To evaluate the antibacterial activity of Doripenem against Pseudomonas aeruginosa FADDI PA070, results showed that Doripenem monotherapy achieved 1.94-4.06 log10 killing at 6 h, but extensive regrowth was observed at 48 h. J Antimicrob Chemother. 2015 May;70(5):1434-42.
Pseudomonas aeruginosa FADDI PA033 1.0 mg/L 240 h To evaluate the antibacterial activity of Doripenem against Pseudomonas aeruginosa FADDI PA033, results showed that Doripenem monotherapy achieved 1.94-4.06 log10 killing at 6 h, but extensive regrowth was observed at 48 h. J Antimicrob Chemother. 2015 May;70(5):1434-42.
Pseudomonas aeruginosa ATCC 27853 0.5 mg/L 240 h To evaluate the antibacterial activity of Doripenem against Pseudomonas aeruginosa ATCC 27853, results showed that Doripenem monotherapy achieved 1.94-4.06 log10 killing at 6 h, but extensive regrowth was observed at 48 h. J Antimicrob Chemother. 2015 May;70(5):1434-42.
Acinetobacter baumannii ATCC 19606 25 mg/L 1 h 45 differentially expressed genes were detected, involved in biofilm formation and carbohydrate degradation J Antimicrob Chemother. 2015 May;70(5):1303-13.
Acinetobacter baumannii ATCC 19606 25 mg/L 15 min No differentially expressed genes were detected J Antimicrob Chemother. 2015 May;70(5):1303-13.
Acinetobacter baumannii N16870 5.25, 10.5, 21, 31.5, 42 mg/L 48 h To evaluate the bactericidal effect of Doripenem in combination with polymyxin B (PMB) against carbapenem-resistant Acinetobacter baumannii. Results showed that Doripenem combined with PMB achieved reductions at the limit of detection (100 CFU/mL) at an inoculum of 106 CFU/mL, while the maximum reduction at 108 CFU/mL was 1.6 log10 CFU/mL. Int J Antimicrob Agents. 2016 Dec;48(6):719-724.
Acinetobacter baumannii 03-149-1 5.25, 10.5, 21, 31.5, 42 mg/L 48 h To evaluate the bactericidal effect of Doripenem in combination with polymyxin B (PMB) against carbapenem-resistant Acinetobacter baumannii. Results showed that Doripenem combined with PMB achieved a ≥3 log10 CFU/mL reduction within 4 h at an inoculum of 106 CFU/mL, while the maximum reduction at 108 CFU/mL was 3.2 log10 CFU/mL. Int J Antimicrob Agents. 2016 Dec;48(6):719-724.
Klebsiella pneumoniae 0.06 μg/ml 16 to 20 h Determine the MIC of Doripenem against Klebsiella pneumoniae Antimicrob Agents Chemother. 2011 Feb;55(2):836-44.

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice Immunocompetent and neutropenic mouse thigh infection models Intravenous 500 mg/8 h and 2 g/8 h Every 8 h for 24 h To evaluate the in vivo efficacy of Doripenem against NDM-1-producing Enterobacteriaceae. Results showed that despite in vitro resistance, high-dose, prolonged infusion of Doripenem achieved >1-log10 CFU reductions in six of eight clinical strains. Antimicrob Agents Chemother. 2014;58(3):1671-7
C3H/HeJ mice Klebsiella pneumoniae pneumonia model Subcutaneous injection 50 mg/kg Multiple doses over 57 hours To study the antibacterial effect of Doripenem on Klebsiella pneumoniae-infected mice. The results showed that Doripenem significantly reduced the Klebsiella burden in the lungs of mice by 2 log10 CFU/g lung tissue over the first 48 h of the infection Antimicrob Agents Chemother. 2011 Feb;55(2):836-44.

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.28mL

0.46mL

0.23mL

11.40mL

2.28mL

1.14mL

22.80mL

4.56mL

2.28mL

References

 

Historical Records

Categories